Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 16/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12530244 | 0.82 | KMT2A (0.50) | KCNN4NPC1RAB9AKMT2AHPGD | |
| SCHEMBL1500195 | 0.79 | KCNN4 (0.43) | KCNN4KMT2A | |
| SCHEMBL2892214 | 0.79 | GRM1 (0.54) | KCNN4NPC1RAB9A | |
| SCHEMBL2888885 | 0.78 | KCNN4 (0.46) | KCNN4NPC1RAB9AKMT2AHPGD | |
| SCHEMBL29848689 | 0.76 | NOTUM (0.51) | KCNN4NPC1RAB9A | |
| SCHEMBL20162825 | 0.74 | KCNN4 (0.43) | KCNN4NPC1RAB9AKMT2AHPGD | |
| SCHEMBL30037543 | 0.74 | HPGD (0.44) | KCNN4NPC1RAB9AKMT2AHPGD | |
| SCHEMBL17324829 | 0.74 | MAPT (0.64) | KMT2AMEN1PRNP | |
| SCHEMBL30037425 | 0.74 | KCNN4 (0.43) | KCNN4NPC1RAB9AKMT2AHPGD | |
| SCHEMBL30038081 | 0.74 | HTT (0.65) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1764362-A1 | BIARYL DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191389-A1 | Biaryl derivatives | GRM1, GRIN1, GRIN2B | KCNN4 634/4885NPC1 1716/4885RAB9A 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.